Lung Cancer
Bayer funds educational programs for healthcare professionals and patients on NSCLC, TRK-fusion testing, and precision medicine, focusing on biomarkers and targeted therapies.
Funder: Bayer
Due Dates: Rolling (monthly review; submit at least 45 days before program start)
Funding Amounts: No specified maximum; funding based on program scope and proposed budget.
Summary: Supports educational programs for healthcare professionals and patients on non-small cell lung cancer, TRK-fusion testing, and precision medicine.
Key Information: Proposals must align with ACCME guidelines and include detailed educational and budget plans.
Description
Bayer's Oncology Medical Affairs Department invites grant applications for educational programs focused on non-small cell lung cancer (NSCLC), specifically adenocarcinoma. The grant aims to advance knowledge and practice through education on the treatment and management of NSCLC, the role of biomarkers and biomarker-driven testing, and the significance of TRK-fusion and TRK pathway aberrations in cancer. Programs should also address the efficacy and safety of approved TRK inhibitors, strategies for prioritizing treatment, and promote a multi-disciplinary, precision medicine approach, particularly in community and regional healthcare settings. The intended audience includes healthcare professionals (oncologists, pulmonologists, surgeons, pathologists, community HCPs) as well as patients and caregivers.
